Patient Recruitment

Patient Accrual

Our integrated approach to subject recruitment promotes subject trust and understanding by delivering recruitment messages in multiple ways with both the appropriate frequency and consistency.

Through ongoing client communications and technology-based approach, Clinipace Worldwide can identify trends and respond in near real time to fluctuations in media inventory, media saturation, and site enrollment performance. Working together with our clients, we develop a media plan and creative content that best meets the project enrollment goals.

Our creative team will work with you to understand your study objectives and create messaging strategies and programs that include broadcast and print advertising, online campaigns, printed/digital study material, direct response mailings, and public relations.

The rate at which new patients are accrued can make or break a clinical trial’s timeline and budget. When sites are slow to enroll patients, timelines are delayed and related costs go up.

However, slow accrual can be mitigated with real-time visibility into site performance. Through our technology-amplified approach, we bring real-time clarity to potential enrollment problems so they can be addressed much more quickly. At-your-fingertips information allows us to identify trends and deploy resources more appropriately based on fluctuations in media inventory, media saturation, and site enrollment performance.

It used to be that when I asked how many patients had been enrolled in one of our trials, I got five different answers depending on the department to which I directed the question.  What’s more, it took anywhere from 30 minutes to 24 hours to get those five answers.  Now, the answers to these questions are immediately available at my fingertips.  - Study sponsor.

News

Spectranetics chooses Clinipace for cardiovascular device clinical trial

Spectranetics has chosen Clinipace to manage all aspects of EXCImer Laser Randomized Controlled Study to treat FemoropopliTEal In-Stent Restenosis (EXCITE ISR). The study, which will serve as the basis for 510(k) notice submission, will enroll up to 353 patients across 30 sites in the US.

Plexxikon selects Clinipace to manage trials

Plexxikon, a company focused on the discovery and development of novel small molecule pharmaceuticals to treat human disease, has selected Clinipace Worldwide, a digital CRO, to manage all aspects of four clinical trials comprising a phase I healthy volunteer study, a phase Ib rheumatoid arthritis (RA) study and two phase II oncology studies. 


Clinipace Worldwide
© 2013 CLINIPACE. All Rights Reserved. Website Privacy Statement | US-EU Safe Harbor | eLinks